← Leaderboards
Venkatakrishna R Jala
University Of Louisville
$3,533,493
Attributed
$3,533,493
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $726.3K · FY2006–25$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,533,493 · 6
By mechanism
P20$1,314,532 · 2
R21$1,138,133 · 3
R01$1,080,828 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Louisville
Same institution · by research overlap
- Zhanxiang Zhou$11,702,941
- Gerald W Dryden$910,250
- Manicka V Vadhanam$351,622
- Daniel Tuse$4,660,011
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationPre-Clinical ModelMediatingColitisProductionBacteriaMolecularMicrobialEpithelial CellsPathway InteractionsGut MicrobiotaInflammatoryExhibitsCellsDietFunctional DisorderPomegranateMouse ModelEllagic AcidEllagi-TanninsInterleukin-6BerryAffectBase
Grant awards (14)
AHR-NLRP6 interactions in gut barrier dysfunction and colitis$540,414
R01 · FY2025 · DK · contact PI
AHR-NLRP6 interactions in gut barrier dysfunction and colitis$540,414
R01 · FY2024 · DK · contact PI
Role of urolithin A in progression of alcohol-associated liver disease$185,844
R21 · FY2024 · AA · contact PI
Role of urolithin A in progression of alcohol-associated liver disease$224,969
R21 · FY2023 · AA · contact PI
Novel synthetic analogue of microbial metabolite, Urolithin A, mitigates inflammatory bowel diseases$207,267
P20 · FY2022 · GM · contact PI
Novel synthetic analogue of microbial metabolite, Urolithin A, mitigates inflammatory bowel diseases$209,004
P20 · FY2021 · GM · contact PI
Novel synthetic analogue of microbial metabolite, Urolithin A, mitigates inflammatory bowel diseases$225,976
P20 · FY2020 · GM · contact PI
Novel synthetic analogue of microbial metabolite, Urolithin A, mitigates inflammatory bowel diseases$211,408
P20 · FY2019 · GM · contact PI
Novel synthetic analogue of microbial metabolite, Urolithin A, mitigates inflammatory bowel diseases$215,600
P20 · FY2018 · GM · contact PI
PQ-10: Microbial metabolite, Urolithin A is a potent immunomodulator and chemosensitizing adjuvant in treating colon cancer.$200,970
R21 · FY2018 · CA · contact PI
PQ-10: Microbial metabolite, Urolithin A is a potent immunomodulator and chemosensitizing adjuvant in treating colon cancer.$167,475
R21 · FY2017 · CA · contact PI
CCR2 mediated inflammation and gut microbiota in promoting intestinal cancer$163,125
R21 · FY2016 · CA · contact PI
CCR2 mediated inflammation and gut microbiota in promoting intestinal cancer$195,750
R21 · FY2015 · CA · contact PI
COBRE: LOUISVILLE RF INC: P4: [RECRUIT EXPECTED TO COME 06/2006]$245,277
P20 · FY2006 · RR · contact PI